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Solid tumours are not a mass of neoplastic cells in isolation; rather,
they are a complex matrix of many cellular types that often
outnumber the tumour cell population. Indeed, macrophages can
account for up to 50% of the tumour mass in breast carcinoma
(Kelly et al, 1988; O’Sullivan and Lewis, 1994; Leek et al, 1994).
Macrophages are known to be involved in the angiogenic process,
and can be stimulated in hypoxic, avascular regions of the tumour
microenvironment to secrete a wide range of angiogenic factors,
including vascular endothelial growth factor (VEGF), basic
fibroblast factor (bFGF), tumour necrosis factor a (TNFa),
endothelial growth factor (EGF), interferons, and others (Leek 
et al, 1997). Additionally, tumour hypoxia alone can also alter the
effects of growth factors and cytokines, induce transcription
factors and DNA repair enzymes, and has been associated with
increased tumour aggressiveness (Brizel et al, 1996; Dachs and
Stratford, 1996). This led us to speculate that hypoxia may be
acting as a stimulus for macrophage infiltration to help elicit the
angiogenic response, and therefore the percentage of host cells
within the tumour mass may correlate with, and provide a 
surrogate marker for, tumour hypoxia. 
Tumour hypoxia is a major cause of radioresistance, and can
also influence the efficacy of chemotherapy (Gray et al, 1953;
Teicher et al, 1981). Measurements of oxygen tension in human
tumours using polarographic microelectrodes have demonstrated
the existence of large hypoxic fractions (Höckel et al, 1993; Brizel
et al, 1996; Nordsmark et al, 1996; Collingridge et al, 1999), and
other studies have shown that human tumour pO2 can be modified
to improve therapeutic response (Saunders and Dische, 1996;
Hoskin et al, 1997). The use of polarographic electrodes is re-
stricted however by their invasive nature, and their limited accessi-
bility to superficial tumours or sites exposed during surgery.
Deep-seated tumours of the bowel and digestive tract, for
example, are not usually available for measurement. Non-invasive
approaches utilizing MRI and PET are currently in development,
and it is possible that surrogate markers that strongly correlate
with tumour hypoxia may open other avenues of non-invasive pO2
measurement. A routine method of assessing tumour oxygenation
prior to, and during, therapy would allow monitoring of treatment
efficacy, modification of treatment schedules as necessary, 
and individualization of therapy according to the patients’ own
physiology. 
In this paper, we demonstrate that the infiltration of IgG-binding
immune cells into solid experimental tumours strongly correlate
with tumour hypoxia, and appear to be predominately derived
from a macrophage lineage. 
MATERIALS AND METHODS 
Animals and tumour models 
8 murine tumour models were used in this investigation. The
anaplastic sarcoma F (SaF), and the adenocarcinomas NT (CaNT),
X (CaX), and WW (CaWW) were transplanted subcutaneously
into the rear dorsum of female CBA/Gy f TO mice. The methyl-
cholanthrene-induced fibrosarcoma R (FsaR), the spontaneous
fibrosarcoma N (FSaN), and the radiation-induced fibrosarcoma,
RIF-1, were grown subcutaneously in the rear dorsum of female
C3H/Gy f BXC/2 mice, and the adenocarcinoma RD (CaRD) was
grown subcutaneously in the rear dorsum of female WHT/Gy 
f C57 B1 mice. SaF, CaNT, CaX, CaWW, and CaRD tumours
arose spontaneously in the Gray Laboratory mouse colonies and
were isolated and characterized between 1957 and 1980. FsaR and
FsaN tumours were derived from the murine FSA fibrosarcoma
(Milas et al, 1975, 1984), and the RIF-1 tumour was originally
characterized by Twentyman et al (1980). All tumours, excluding
RIF-1, were serially maintained by injecting 0.05 ml of a crude
cell suspension prepared by mechanical dissociation of an excised
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tumour from a donor animal. RIF-1 tumours were inoculated by
injecting 5 ´ 105 cells from exponentially growing cell cultures
suspended in 0.05 ml of PBS. Tumours were selected for treatment
when they had reached 5–8 mm in diameter (100–300 mg). All
animal experiments were performed in full compliance with
government regulations and UKCCCR guidelines on animal
welfare. 
Immune cell determination 
2 fluorescein-labelled antibodies were used to assess the propor-
tion of infiltrating immune cells in each tumour line by flow
cytometry. Cell suspensions were labelled with a non-specific
polyclonal antibody (goat anti-mouse IgG/FITC; Sigma-Aldrich
Company Ltd, Dorset, UK), which binds to macrophages and
other polymorphs, to determine a gross indication of the immune
cell content. Cell suspensions from the SaF, CaNT, and FSaN
tumours where also incubated with a monoclonal antibody (rat
anti-mouse F4/80/FITC; Serotec Ltd, Kidlington, Oxford, UK)
directed against the macrophage-specific F4/80 antigen (Hume
and Gordon, 1983). Tumour cell suspensions were obtained by
excising solid tumours from host mice. A minimum of 3 tumours
were assayed for each tumour line. The excised material was
minced and enzymatically digested for 30 minutes at 37˚C with
either Collagenase (type II; 2 mg ml–1; activity, >125 U mg–1), or
Dispase (20 mg ml–1; activity, >6 U mg–1) dissolved in Hanks
medium (Sigma-Aldrich Company Ltd, Dorset, UK). Both
methods of digestion also contained DNase (type I; 0.2 mg ml–1;
activity, 420 U mg–1). Following digestion, Hanks medium
containing 7% fetal bovine serum was added to neutralize the
enzymes and the samples were passed through a 25G needle and a
35 mm filter to obtain a single cell suspension. The suspensions
were centrifuged and resuspended in cold PBS and placed on ice.
All samples where kept ice-cold to inhibit polymorph activity and
prevent phagocytosis of reagents. 
To label the samples, cell suspensions were fixed with 
ice-cold 70% ethanol, and then washed and resuspended in PBS
at a concentration of 7.5 ´ 105 cells ml–1. To 2 ml aliquots, 20 ml
of neat IgG/FITC or 80 ml of F4/80/FITC (diluted 1:4 in 
Trizma buffer) was added. Samples were then incubated on 
ice for 5 minutes (IgG/FITC) or 30 minutes (F4/80/FITC).
Following incubation, samples were washed and resuspended 
in PBS and passed through a 25G needle. Finally, RNase (type I;
1 mg ml–1; activity, 50–100 U mg–1) and propidium iodide 
(1 mg ml–1) were added, and the samples analysed by flow
cytometry (FACScan; Becton-Dickinson UK Ltd, Cowley,
Oxford, UK) to determine the proportion of cells positively
labelled with FITC. 
Immune cell distributions were assessed for the SaF and 
FSaN tumours using Hoechst 33342 (4 mg ml–1; Sigma-Aldrich
Company Ltd, Dorset, UK). This dye penetrates tumour tissue
producing a gradient of fluorescence (visible in the u.v. range) that
identifies the position of cells in situ relative to any functional
vasculature (Chaplin et al, 1985). Mice were given 0.1 ml intra-
venous injections of Hoechst 33342 20 minutes prior to tumour
excision. Tumours were then labelled for immune cell content as
described earlier. Using a Vantage Cell Sorter (Becton-Dickinson
UK Ltd, Cowley, Oxford, UK) the distribution of Hoechst staining
amongst the immune cells positively labelled for FITC was 
determined. 
Measurement of oxygen tension 
Oxygen measurements were performed using a pO2 histograph
(Eppendorf KIMOC 6650, Hamburg, Germany). Full operational
details for this machine are described elsewhere (Collingridge 
et al, 1997). Briefly, un-anaesthetized tumour-bearing mice were
restrained in Perspex jigs exposing the rear dorsum. A reference
Ag/AgCl electrode (Medicotest UK Ltd, St Ives, Cambridgeshire,
UK) was attached to a shaved region on the back of each animal,
and the jig was placed on a thermal barrier (Vetko, CO, USA) to
maintain core temperature. Using a net step length of 0.6 mm,
40–70 pO2 measurements were made from 6 tracks through each
tumour. 5–35 tumours were measured for each experimental
model. All oxygen measurements were post-calibrated to account
for barometric pressure and tumour temperature. The median pO2
and the percentage of pO2 readings <2.5 mmHg was calculated for
each tumour and then averaged for each experimental model. 
RESULTS 
Figure 1 shows the results from a representative sarcoma F tumour
labelled with both FITC conjugated IgG (Figure 1A) and FITC
conjugated F4/80 (Figure 1B). The graphs depict similar cell
distributions; with the upper populations representing positively
stained immune cells. The number of IgG-positive cells, as a
proportion of the entire cell population, was approximately 40% in
this tumour model. Table 1 shows the immune cell content of 
the other tumours. The IgG-positive component of these tumours
ranged from approximately 20% to 50%. F4/80 labelling of the
CaNT and the FSaN tumours indicated that the immune com-
ponent was composed almost entirely of macrophages. Preliminary
F4/80 labelling data from the SaF tumour (also shown in Figure 1)
is broadly similar to the CaNT and FSaN tumours, indicating that
a significant proportion of the infiltrating IgG-positive immune
cells in the SaF were also macrophages. 
Intravenous injections of Hoechst 33342 stained cells according
to their position within the tumour. Figure 2 shows the distribution
of Hoechst 33342 labelling of the SaF. Tumour cells, with a low
affinity for IgG (Figure 2A), showed a Hoechst 33342 labelling
profile (Figure 2C), which indicated a large number of cells with a
strong incorporation of the dye, whilst progressively fewer propor-
tions of cells with lesser degrees of incorporation, in other words,
the data shows a gradient of staining extending from functional
vasculature into less vascular regions. Additionally, the Hoechst
33342 profile (Figure 2D) for the IgG labelled immune cells
(Figure 2B) was near identical to the tumour cell labelling, 
thus indicating the presence of immune cells distant from the
Table 1 Percentage of immune cells in 8 experimental murine tumours 
Tumour IgG positive (%) *SEM F4/80 positive (%) *SEM 
CaX 19.9 1.6 – – 
FsaR 33.9 6.3 – – 
CaNT 36.1 2.6 34.2 2.0 
SaF 39.8 2.2 27.5a – 
CaWW 47.7 4.4 – – 
CaRD 50.5 3.4 – – 
RIF-1 51.0 1.9 – – 
FSaN 51.0 2.1 51.4 5.6 
Minimum of 3 tumours per determination, except a = average of 2 tumours.
*Errors are ± 1 SEM vasculature. Experiments combining F4/80 with Hoechst 33342 to
label macrophages within FSaN tumours showed similar results
(data not shown). 
Measurements of oxygen tension within the 8 types of tumour
varied significantly. The median pO2s ranged from 0.4 mmHg for
the FSaN to 3.1 mmHg for the CaX, whilst the percentage of 
pO2 readings less than 2.5 mmHg ranged from 46.3% to 89.4%.
Figure 3 correlates the oxygen tensions of the solid tumours with
their corresponding IgG-positive immune cell contents. There is a
strong correlation between the 2 parameters indicating that with
decreasing oxygenation, or conversely, increasing hypoxic frac-
tion, the proportion of immune cells binding to IgG within the
tumour mass increased. 
DISCUSSION 
Macrophages represent a major component of the lymphoreticular
infiltrate in tumours. In this paper, we demonstrate that up to 50%
of the total tumour volume can be attributable to IgG-binding
immune cells, which appear to be comprised predominately of
macrophages. Other investigators have also reported large propor-
tions of tumour-associated macrophages. Milas and colleagues
(1987) have shown the macrophage content in a variety of murine
tumours can vary from 9 to 83%, whilst Olive (1989) identified a
macrophage content of between 20–60% in the murine SCCVII
carcinoma. Similarly, tumour-associated macrophage content in
human tumours can also be high. In a study of 20 human tumour
biopsies of differing histology, Svennevig et al detected up to 28%
of the biopsied tissue contained macrophages (1979). More
recently, high proportions of macrophages have been measured in
human breast carcinoma (Leek et al, 1997, 1999). 
The data presented here does not allow us to comment on the
absolute distribution of macrophages in the tumour mass. Hoechst
33342 stains cells relative to their distance from functional vascu-
lature in accordance with the diffusion properties of the dye. The
distribution profile shown in Figure 2D indicates that some cells
were labelled weakly, and therefore they must have been at the
limits of the diffusible range for Hoechst 33342. One can conclude
that these cells must have migrated from the blood vessels into the
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Figure 1 Labelling of immune cells in a representative SaF tumour. Panel
A: Sample labelled with polyclonal IgG antibodies. Panel B: Sample labelled
with monoclonal antibodies directed against the macrophage-specific F4/80
antigen. Both antibodies were conjugated to FITC and cell labelling was
assessed by flow cytometry 
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Figure 2 Distribution of immune cells within a representative SaF tumour.
Panel A: Tumour cells with low affinity to IgG-FITC. Panel B: Immune cells
labelled with IgG-FITC. Panel C: Distribution of Hoechst 33342 vital dye
amongst tumour cells. Panel D: Distribution of Hoechst 33342 vital 
dye amongst IgG-positive immune cells. Analysis was performed using flow
cytometry Tumour hypoxia and immune cell content 629
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tumour mass; but the data does not provide any information
regarding the proportion of cells in the avascular regions beyond
the diffusible range of the dye, and it is therefore not possible to
comment on the extent of infiltration of either IgG-positive
immune cells or macrophage cells into the avascular necrotic
regions of the tumour. 
The role of macrophage recruitment to neoplastic tissue is
complex, since macrophages have numerous functions related to
tissue remodelling, inflammation, immunity and thrombosis. Thus
they have the capacity to affect tumour vascularization, growth
rate, stroma formation, and apoptotic cell death (Mantovani et al,
1992). Leek et al (1997) have shown that higher numbers of
macrophages are found in angiogenic breast tumours and that they
are concentrated in avascular, hypoxic regions of the tumour,
consistent with many other reports indicating high macrophage
numbers in avascular necrotic sites (Lewis et al, 1999). Hypoxia is
known to stimulate the angiogenic activity of macrophages, and
macrophage-derived VEGF is upregulated under low oxygen
tensions (Harmey et al, 1998). Furthermore, the macrophage-
derived peptide, PR39, can prevent degradation of hypoxia-
inducible-factor 1a (HIF-1) and, because HIF-1 is an upstream
regulator of VEGF, this can promote angiogenesis (Li et al, 1999;
Ozaki et al, 2000). 
It has been suggested, that macrophages are attracted to the
tumour matrix by following a falling oxygen gradient or by
chemoattractants released from stressed or necrotic cells (Leek
et al, 1997). Consistent with these theories, breast cancer patients
with low macrophage indices have a lower risk of recurrence and
increased overall survival rates (Leek et al, 1997), furthermore,
experimental studies have shown a trend between high macro-
phage numbers and radioresistance (Milas et al, 1987). These
studies suggest that radiobiologically hypoxic tumours are targets
for angiogenic activity, presumably to improve nutrient supply and
drainage, and unsurprisingly have poor response rates to therapy.
The results presented in this paper are in agreement with these
conclusions. We show, amongst a range of experimental tumours,
that those tumours exhibiting the highest levels of hypoxia also
contain the highest proportions of IgG-binding immune cells.
Furthermore, additional experimental data, that is not presented in
this paper, provides us with little evidence to suggest that these
cells are attracted to tumours containing high necrotic fractions to
facilitate dead cell clearance; this leads us to conclude therefore,
that hypoxia plays a key role in IgG-positive immune cell 
migration. It is important to highlight that the tumour models used
in this study exhibit a range of oxygen tensions at the lower end of
the spectrum, and further work is now needed to evaluate the
immune cell content in well oxygenated tumours to examine the
full dynamic range of the relationship. Furthermore, it would be
useful to determine the strength of the relationship between
tumours of the same type, and thereby examine a more clinically
relevant endpoint, namely, whether one patient could be distin-
guished from another, rather than groups of patients from each
other. 
A strong correlation between IgG-positive immune cell content
and tumour hypoxia may potentially offer an alternative method
of measuring oxygenation. Non-invasive methods of detecting
tumour hypoxia using MRI, EPR and PET are currently in devel-
opment (Aboagye et al, 1998; O’Hara et al, 1998; Evans et al,
2000). PK11195, for example, binds to activated macrophages
(Zovala and Lenfant, 1987), and PET studies using 11C-PK11195
at Hammersmith hospital are being conducted to image macro-
phage infiltration during neuro-inflammation in Rasmussen’s
encephalitis (Banati et al, 1999); thus it may be possible to utilize
this imaging approach to indirectly measure tumour hypoxia in
addition to macrophage activation states. Furthermore, macro-
phage measurement may evade the potential risks associated with
many conventional nitroimidazole-based hypoxic markers, which
can have mutagenic and carcinogenic effects (Voogd, 1981;
Tocher, 1997). 
In conclusion, this paper shows that the proportion of IgG-
binding immune cells in solid tumours correlates with the degree
of hypoxia, and that decreased oxygen gradients may act as a 
stimulus for cell recruitment to neoplastic tissue. Furthermore, a
majority of the IgG-positive cells appear to be of a macrophage
lineage, and thus the detection of macrophages may provide an indi-
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Figure 3 Correlation between oxygen tension and the proportion of 
IgG-binding immune cells for eight murine tumours. Panel A: Average
median pO2 versus immune cell content. Panel B: Average percentage of
pO2 values <2.5 mmHg versus immune cell content. The fit is a linear
regression, with the representative r value indicated in each panel. Errors are
± 1 S.E.M. pO2 values derived from 5–35 tumours depending on cell line,
immune content derived from a minimum of 3 tumours per cell line 630 DR Collingridge et al 
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